ARNA Description — Arena Pharmaceuticals Inc

Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics. Co.'s clinical programs include: Etrasimod, which Co. is evaluating in a Phase 3 program for ulcerative colitis, a Phase 2b/3 program for Crohn's disease, a Phase 2 program in alopecia areata, and a Phase 2b program for eosinophilic esophagitis; APD418, which is for acute heart failure; Temanogrel, which is in a Phase 2 trial for microvascular obstruction, and a Phase 2 trial for Raynaud's phenomenon secondary to systemic sclerosis; and Olorinab, which Co. is evaluating for a range of visceral pain conditions associated with gastrointestinal diseases.

Company Name: 
Arena Pharmaceuticals Inc
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree ARNA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (2.60 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding ARNA | Arena Pharmaceuticals Inc | ETF Channel |

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.